BARONI, Marcello
 Distribuzione geografica
Continente #
NA - Nord America 3.333
EU - Europa 997
AS - Asia 690
OC - Oceania 10
SA - Sud America 9
Continente sconosciuto - Info sul continente non disponibili 3
Totale 5.042
Nazione #
US - Stati Uniti d'America 3.305
CN - Cina 305
IT - Italia 293
SG - Singapore 203
DE - Germania 174
UA - Ucraina 154
GB - Regno Unito 105
TR - Turchia 98
PL - Polonia 63
SE - Svezia 56
FI - Finlandia 44
ID - Indonesia 35
BE - Belgio 30
CA - Canada 26
CZ - Repubblica Ceca 18
NL - Olanda 18
HK - Hong Kong 15
VN - Vietnam 14
AU - Australia 10
FR - Francia 9
RU - Federazione Russa 9
JP - Giappone 7
PE - Perù 7
LT - Lituania 6
RO - Romania 6
ES - Italia 4
IN - India 4
IR - Iran 3
BR - Brasile 2
EU - Europa 2
GE - Georgia 2
IE - Irlanda 2
MX - Messico 2
A2 - ???statistics.table.value.countryCode.A2??? 1
DK - Danimarca 1
HU - Ungheria 1
IL - Israele 1
KR - Corea 1
LK - Sri Lanka 1
MK - Macedonia 1
NO - Norvegia 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 5.042
Città #
Fairfield 383
Woodbridge 361
Chandler 274
Santa Clara 216
Houston 206
Ann Arbor 190
Ashburn 179
Jacksonville 168
Seattle 162
Singapore 158
Wilmington 150
Ferrara 148
Cambridge 123
Boardman 74
Izmir 66
Warsaw 62
Nanjing 59
Princeton 56
Beijing 55
New York 46
Milan 38
Dearborn 37
Jakarta 35
Shanghai 35
Bremen 32
San Diego 31
Brussels 25
Falls Church 23
Nanchang 22
Shenyang 22
Munich 20
Los Angeles 18
Brno 16
Redwood City 16
Hebei 14
Hong Kong 14
Norwalk 14
Dong Ket 13
Helsinki 13
Guangzhou 12
Jiaxing 12
Mcallen 11
Toronto 11
London 10
Florence 9
San Mateo 9
Tianjin 9
Verona 9
Frankfurt am Main 8
Montréal 8
Auburn Hills 7
Des Moines 7
Zhengzhou 7
Abdullah 6
Augusta 6
Bologna 6
Changsha 6
Ottawa 6
Jinan 5
Kunming 5
Lima 5
Monmouth Junction 5
Mountain View 5
Tokyo 5
Chicago 4
Fuzhou 4
Leawood 4
Louvain 4
Rome 4
Washington 4
Castellarano 3
Cento 3
Düsseldorf 3
Haikou 3
Hounslow 3
Indiana 3
Lleida 3
Lusia 3
Palermo 3
Reading 3
Redmond 3
Taizhou 3
Wuhan 3
Adana 2
Albignasego 2
Argentan 2
Ariano nel Polesine 2
Dronten 2
Falkenstein 2
Hangzhou 2
Hefei 2
Imola 2
Kilburn 2
Lappeenranta 2
Lockport 2
Marienheide 2
Melbourne 2
Meppel 2
Miami 2
Minerbio 2
Totale 3.860
Nome #
Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study 168
Stimulation of P2 (P2X7) receptors in human dendritic cells induces the release of tissue factor-bearing microparticles. 157
Hemostasis biomarkers in multiple sclerosis 152
The carboxyl-terminal region is NOT essential for secreted and functional levels of coagulation factor X 147
Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events. 145
Changes in expression profiles of internal jugular vein wall and plasma protein levels in multiple sclerosis 140
Genetic determinants of activated factor VII antithrombin complex plasma concentration include tissue factor, factor VII and endothelial protein C receptor gene variants 139
Responsiveness of hemophilia B- causing non sense mutations to ribosome readthrough-inducing drugs strictly depends on the nucleotide and prrotein context 136
Factor II Activity is Similarly Increased in Patients With Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 125
Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation 124
The carboxyl-terminal region is not essential for secreted and functional levels of coagulation factor X 123
Plasma levels of soluble NCAM in multiple sclerosis 123
Membrane binding and anticoagulant properties of protein S natural variants 119
Coagulation Factor XII Levels and Intrinsic Thrombin Generation in Multiple Sclerosis 118
Molecular bases of type II protein S deficiency: the I203-D204 deletion in the EGF4 domain alters GLA domain function 113
Tissue Factor and Coagulation Factor VII Levels during Acute Myocardial Infarction Contribute to Predict Mortality and re-infarction. 110
Factor II Activity is Similarly Increased in Patients with Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 107
Impaired prothrombinase activity of factor X Gly381 Asp results in severe familial CRM+ FX deficiency 106
Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition 103
Apolipoprotein C-III Strongly Correlates with Activated Factor VII-Anti-Thrombin Complex: An Additional Link between Plasma Lipids and Coagulation 100
Expression profiles of the internal jugular and saphenous veins: Focus on hemostasis genes 99
Non-conventional therapeutic strategies for inherited disorders oh hemostasis 97
Human protein S circulates in plasma partially bund to LDL and HDL: do PS-lipoprotein complexes mediate PS delivery within atherosclerotic plaque? 96
Increased CCL18 plasma levels are associated with neurodegenerative MRI outcomes in multiple sclerosis patients 96
null 94
null 93
Reduced activation of the Gla19Ala FX variant via the extrinsic coagulation pathway results in symptomatic CRMred FX deficiency 92
Release of Tissue Factor-bearing microparticles by human dendritic cells induced by stimulation of membrane P2X7 receptors 90
Functional recovery in multiple sclerosis patients undergoing rehabilitation programs is associated with plasma levels of hemostasis inhibitors 86
Activated factor VII: antithrombin complex plasma concentration in subjects with or without angiographically demonstrated coronary artery disease and myocardial infarction 85
Expression Profiles of the Internal Jugular and Saphenous Veins: Focus on Hemostasis Genes 85
null 84
TRATTAMENTO E PREVENZIONE DI MALATTIE CARDIOVASCOLARI CON ACIDO ERUCICO E METODI DIAGNOSTICI CORRELATI 83
THE NATURAL ARG386CYS MUTATION IN THE COAGULATION FACTOR X, AS A TOOL TO INVESTIGATE DIFFERENT FX-REQUIREMENTS IN INITIATION AND PROPAGATION PHASES. 78
Plasma levels of protein C pathway proteins and brain magnetic resonance imaging volumes in multiple sclerosis 78
null 73
Natural mutations in the EGF4 domain of protein S produce extended conformational changes and alter phospholipid and C4bBP interactions 71
The effect of the chemical chaperone 4-phenylbutyrate on secretion and activity of the p.Q160R missense variant of coagulation factor FVII 69
The F7 p.Val22Ile missense mutation affects splicing and can be counteracted by a compensatory U1snRNA 65
Non-conventional therapeutic strategies for inherited disorders of hemostasis 64
Molecular characterization of factor X deficiency associated with borderline plasma factor X level 62
Mutation-specific contributions to trace factor X levels account for a life-threating phenotype in a compound heterozygous factor X deficient patient 62
NATURAL MUTATIONS IN THE EGF4 DOMAIN OF PROTEIN S PRODUCE EXTENDED CONFORMATIONAL CHANGES AND ALTER PHOSPHOLIPID AND C4BBP INTERACTIONS 58
null 56
RNA-based therapeutic approaches for blood coagulation factor deficiencies caused by a splicing mutations 53
Hemostasis gene expression of the internal jugular and saphenous veins 53
Basophil Blood Cell Count Is Associated With Enhanced Factor II Plasma Coagulant Activity and Increased Risk of Mortality in Patients With Stable Coronary Artery Disease: Not Only Neutrophils as Prognostic Marker in Ischemic Heart Disease 49
null 45
The Factor VII Variant p.A354V-p.P464Hfs: Clinical versus Intracellular and Biochemical Phenotypes Induced by Chemical Chaperones 43
CCL18 plasma levels are increased in progressive MS patients and associated with MRI outcomes of tissue injury (P1.396) 42
In Situ Endothelial SARS-CoV-2 Presence and PROS1 Plasma Levels Alteration in SARS-CoV-2-Associated Coagulopathies 39
Plasma levels of hemostasis inhibitors and MRI outcomes in multiple sclerosis (P3.368) 39
Aptamer-modified FXa generation assays to investigate hypercoagulability in plasma from patients with ischemic heart disease 38
RNA−based therapeutic approaches for blood coagulation factor deficiencies caused by splicing mutations 36
Crosstalk between hemostasis inhibitors and cholesterol biomarkers in multiple sclerosis 35
Combination of Genomic and Transcriptomic Approaches Highlights Vascular and Circadian Clock Components in Multiple Sclerosis 34
Protein S on the surface of plasma lipoproteins: a potential mechanism for protein S delivery to the atherosclerotic plaques? 32
EFFECT OF SARS-CoV-2 ON THE COAGULATION CASCADE IN COVID-19 ASSOCIATED COAGULOPATHIES 32
Coagulation factor VII variants resistant to inhibitory antibodies. 21
Coagulation factor VII variants resistant to inhibitory antibodies 21
Suppression of “leaky” nonsense mutations by ribosome readthrough accounts for residual factor IX levels in Haemophilia B patients 20
Mapping of inhibitory antibodies directed to the carboxy-terminus of FVIIa in severe FVII deficiency with elongated C-terminal variant (p.A354V-p.P464Hfs†) 20
Relationships among circulating levels of hemostasis inhibitors, chemokines, adhesion molecules, and mri characteristics in multiple sclerosis 19
Treatment and prophylaxis of cardiovascular disorders with erucic acid and related diagnostic methods 19
Immune response to treatment in a severe factor VII deficient patient: characterization of the inhibitory antibody and epitope-mapping 18
Natural Mutations in the 4th EGF-Like Domain of Protein S Alter GLA and SHBG Domain Interactions. 5
Totale 5.184
Categoria #
all - tutte 26.430
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.430


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020520 0 0 0 0 0 122 90 95 69 78 41 25
2020/2021820 47 42 27 97 25 58 81 80 50 145 123 45
2021/2022636 84 70 22 28 24 29 26 35 18 49 44 207
2022/2023634 60 64 23 87 92 88 46 50 67 8 37 12
2023/2024436 27 33 15 10 32 64 22 48 12 16 10 147
2024/2025580 33 41 143 47 170 146 0 0 0 0 0 0
Totale 5.184